LONDON Jan 8 (Reuters) - Wyeth's WYE.N established drug Enbrel has been approved by the European Commission as the first biologic treatment for children with severe plaque psoriasis, the U.S. company said on Thursday.
The formal green light for the new indication had been expected, following a positive recommendation from the European Medicines Agency in November. Enbrel is best known as a treatment for rheumatoid arthritis. (Reporting by Ben Hirschler; Editing by David Holmes)